-
18193-5A dihydropteridinone that inhibits Plk1, Plk2, and Plk3 (IC<sub>50</sub>s = 0.87, 5, and 56 nM, respectively), inducing mitotic arrest and apoptosis inhibits proliferation of multiple cancer cell lines (EC<sub>50</sub>s = 11-37 nM) and prevents the
-
17265-1An inhibitor of tBid (Kd = 20 µM), blocking the release of both cytochrome c and Smac from mitochondria prevents apoptosis in neurons treated with glutamate or oxygen-glucose deprivation inhibits the nuclear translocation of AIF, preventing
-
17265-10An inhibitor of tBid (Kd = 20 µM), blocking the release of both cytochrome c and Smac from mitochondria prevents apoptosis in neurons treated with glutamate or oxygen-glucose deprivation inhibits the nuclear translocation of AIF, preventing
-
17265-5An inhibitor of tBid (Kd = 20 µM), blocking the release of both cytochrome c and Smac from mitochondria prevents apoptosis in neurons treated with glutamate or oxygen-glucose deprivation inhibits the nuclear translocation of AIF, preventing
-
20311-1A potent BRD9 bromodomain inhibitor.
-
20311-10A potent BRD9 bromodomain inhibitor.
-
20311-25A potent BRD9 bromodomain inhibitor.
-
20311-5A potent BRD9 bromodomain inhibitor.
-
18301-1A selective dual MEK/Aurora kinase inhibitor (IC<sub>50</sub>s = 3, 25, 15, 25, and 4 nM for X. laevis Aurora B, human Aurora A and Aurora C, and human MEK1 and MEK2, respectively) inhibits the growth and survival of both treatment-naïve and
-
18301-5A selective dual MEK/Aurora kinase inhibitor (IC<sub>50</sub>s = 3, 25, 15, 25, and 4 nM for X. laevis Aurora B, human Aurora A and Aurora C, and human MEK1 and MEK2, respectively) inhibits the growth and survival of both treatment-naïve and
-
17897-1A selective inhibitor of BRD9 and BRD7 bromodomains (Kds = 14.1 and 239 nM IC<sub>50</sub>s = 75 nM and 3.
-
17897-10A selective inhibitor of BRD9 and BRD7 bromodomains (Kds = 14.1 and 239 nM IC<sub>50</sub>s = 75 nM and 3.